SeaBeLife, a biotechnology company based in Roscoff, France, has announced in vivo clinical results for its SBL03 drug candidate, an ophthalmic gel aimed to combat… Read More »SeaBeLife, a biotech company based in Roscoff, France, announce preliminary results on preclinical models for a new class of drugs for geographic atrophy (GA).
RhyGaze AG, based in Basel, Switzerland and Philadelphia, Pa., USA, have announced a Series A financing of USD $86 million for their company, aimed to… Read More »RhyGaze AG (Switzerland) receives $86M funding for optogenetic vision restoration, a spin-out of the Institute of Molecular and Clinical Ophthalmology, Basel.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced that aflibercept (injection 8 mg) met the primary endpoint for the treatment of patients with macular oedema following… Read More »Aflibercept injection (8 mg, Eylea HD) for the treatment of macular oedema following retinal vein occlusion (RVO) meets primary endpoint.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company based in Iselin, New Jersey, USA, has announced that the UK NICE (National Institute for Health and… Read More »Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of… Read More »The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).
Life sciences company AlloVir, Inc. (NASDAQ: ALVR), based in Watham, Mass. and Palo Alto, California, have announced a merger agreement to combine with Kalaris Therapeutics… Read More »AlloVir and Kalaris Therapeutics have announced a merger to support a new anti-VEGF opportunity.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data for an ongoing Phase 2 “VERONA” clinical trial, evaluating “DURAVYU”… Read More »EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.
Ocuphire Pharma, Inc. (Nasdaq: OCUP), based in Farmington Hills, Michigan, USA announced the all-stock acquisition of Opus Genetics, Inc., a private ocular gene therapy company… Read More »Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.
Delegates at the EURETINA Congress in Barcelona (Sept. 20th 2024) have heard new outcome data from a real-world study on faricimab (anti-VEGF, Vabymso), for naïve… Read More »Roche supported by a real-world study with initial outcomes on faricimab at EURETINA Congress – treatment-naïve patients with nAMD and DME (VOYAGER Study).
HuidaGene Therapeutics, based in Shanghai, China and Clinton, New Jersey, have reported preliminary data on a novel gene therapy treatment for RPE-65 LCA (Leber congenital… Read More »HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.
